ESMO 2021 Bladder Cancer

Viewing 1-20 of 27 articles

ESMO 2021: High- vs Low-Dose Pre-Operative Ipilimumab and Nivolumab in Locoregionally Advanced Urothelial Cancer (NABUCCO Cohort 2)

ESMO 2021: Avelumab as the Basis of Neoadjuvant Chemotherapy Regimen in Platinum Eligible and Ineligible Patients with Non-Metastatic Muscle Invasive Bladder Cancer (NM-MIBC)

ESMO 2021: Cisplatin (Cis)-Related Immunomodulation and Efficacy with Atezolizumab + Cis- vs Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer (mUC)

ESMO 2021: Avelumab as the Basis of Neoadjuvant Chemotherapy Regimen in Platinum Eligible and Ineligible Patients with Non-Metastatic Muscle Invasive Bladder Cancer: AURA Trial

ESMO 2021: Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer

ESMO 2021: High- Versus Low-Dose Pre-Operative Ipilimumab and Nivolumab in Locoregionally Advanced Urothelial Cancer: NABUCCO Cohort 2

ESMO 2021: A Discussion on the Results of the GETUG/AFU VESPER V05 Phase III Trial and on Pembrolizumab in Combination with sEphB4-HSA (B4) in a Phase II Trial for Previously Treated Metastatic Urothelial Carcinoma

ESMO 2021: Phase II Trial of Pembrolizumab (P) in Combination with sEphB4-HSA (B4) in Previously Treated Metastatic Urothelial Carcinoma (mUC)

ESMO 2021: GETUG/AFU VESPER V05 Phase III Trial of Dose Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin or Gemcitabine and Cisplatin As Perioperative Chemotherapy for Patients With MIBC

ESMO 2021: IMvigor011: A Global, Double-Blind, Randomized Phase 3 Study of Atezolizumab Versus Placebo As Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Post Cystectomy

ESMO 2021: The Phase 2 NORSE Trial Discussion: A Novel Combination in the First-Line Setting for Patients With Metastatic or Locally Advanced Urothelial Carcinoma and FGFR Alterations

ESMO 2021: Erdafitinib (ERDA) or ERDA Plus Cetrelimab (CET) for Patients With Metastatic or Locally Advanced Urothelial Carcinoma (mUC) and Fibroblast Growth Factor Receptor Alterations (FGFRa): First Phase 2 Results From the NORSE Study

ESMO 2021: Tissue and Blood-Based Biomarkers for Urothelial Cancer

ESMO 2021: Results of the GETUG/AFU VESPER V05 Phase III Trial (ddMVAC vs GC in MIBC) and the Phase II Trial of Pembrolizumab plus sEphB4-HSA in Metastatic Urothelial Carcinoma

ESMO 2021: Phase II Trial of Pembrolizumab (P) in Combination with sEphB4-HSA (B4) in Previously Treated Metastatic Urothelial Carcinoma (mUC)

ESMO 2021: Erdafitinib or Erdafitinib Plus Cetrelimab for Patients with Metastatic or Locally Advanced Urothelial Carcinoma and Fibroblast Growth Factor Receptor Alterations: First Phase 2 Results From the NORSE Study

ESMO 2021: The Phase 2 NORSE Trial Discussion: Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic or Locally Advanced Urothelial Carcinoma and FGFR Alterations

ESMO 2021: Dose-Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with MIBC: GETUG/AFU VESPER V05 Phase III Trial

ESMO 2021: Novel Treatment Strategies in Advanced Urothelial Cancer

ESMO 2021: KEYNOTE-676 Cohort B: Randomized Comparator-Controlled Cohort To Evaluate Efficacy and Safety of Pembrolizumab Plus BCG in Patients With High-Risk BCG Treatment-Naive NMIBC

1
2